Abbisko Cayman Ltd
HKEX:2256
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.17
5.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Abbisko Cayman Ltd
Abbisko Cayman Ltd
Cash from Operating Activities
Abbisko Cayman Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbisko Cayman Ltd
HKEX:2256
|
Cash from Operating Activities
-¥444.7m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Operating Activities
-¥7.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Operating Activities
¥1.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Operating Activities
¥796.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Operating Activities
¥6.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
54%
|
CAGR 10-Years
43%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Operating Activities
¥2B
|
CAGR 3-Years
66%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
Abbisko Cayman Ltd
Glance View
Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
See Also
What is Abbisko Cayman Ltd's Cash from Operating Activities?
Cash from Operating Activities
-444.7m
CNY
Based on the financial report for Dec 31, 2023, Abbisko Cayman Ltd's Cash from Operating Activities amounts to -444.7m CNY.
What is Abbisko Cayman Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-54%
Over the last year, the Cash from Operating Activities growth was -29%. The average annual Cash from Operating Activities growth rates for Abbisko Cayman Ltd have been -54% over the past three years .
You don't have any saved screeners yet
